- Home
- KTTA vs VTAK Comparison
KTTA vs VTAK Comparison
Compare KTTA & VTAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KTTA
- VTAK
- Stock Information
- Founded
- KTTA 2020
- VTAK 2002
- Country
- KTTA United States
- VTAK United States
- Employees
- KTTA N/A
- VTAK N/A
- Industry
- KTTA Biotechnology: Pharmaceutical Preparations
- VTAK Medical/Dental Instruments
- Sector
- KTTA Health Care
- VTAK Health Care
- Exchange
- KTTA Nasdaq
- VTAK Nasdaq
- Market Cap
- KTTA 2.6M
- VTAK 3.1M
- IPO Year
- KTTA 2021
- VTAK 2018
- Fundamental
- Price
- KTTA $1.30
- VTAK $0.35
- Analyst Decision
- KTTA
- VTAK
- Analyst Count
- KTTA 0
- VTAK 0
- Target Price
- KTTA N/A
- VTAK N/A
- AVG Volume (30 Days)
- KTTA 3.3M
- VTAK 149.8K
- Earning Date
- KTTA 03-28-2025
- VTAK 03-31-2025
- Dividend Yield
- KTTA N/A
- VTAK N/A
- EPS Growth
- KTTA N/A
- VTAK N/A
- EPS
- KTTA N/A
- VTAK N/A
- Revenue
- KTTA N/A
- VTAK $399,000.00
- Revenue This Year
- KTTA N/A
- VTAK $38.46
- Revenue Next Year
- KTTA N/A
- VTAK $533.33
- P/E Ratio
- KTTA N/A
- VTAK N/A
- Revenue Growth
- KTTA N/A
- VTAK 27.07
- 52 Week Low
- KTTA $1.25
- VTAK $0.31
- 52 Week High
- KTTA $9.25
- VTAK $4.10
- Technical
- Relative Strength Index (RSI)
- KTTA 30.34
- VTAK 34.81
- Support Level
- KTTA $1.32
- VTAK $0.33
- Resistance Level
- KTTA $1.38
- VTAK $0.43
- Average True Range (ATR)
- KTTA 0.26
- VTAK 0.03
- MACD
- KTTA -0.05
- VTAK -0.00
- Stochastic Oscillator
- KTTA 1.92
- VTAK 17.00
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia.
About VTAK Catheter Precision Inc.
Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System) which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.